Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

The secrets of idiopathic pulmonary fibrosis (IPF) are written in its very name. Idiopathic refers to a disease of unknown ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 ...

United Therapeutics’ first quarter results came in above Wall Street’s expectations, but the market reacted negatively, with ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive ...

Mediar's third novel fibrosis program, targeting SMOC2 for renal fibrosis, is also advancing with a plan to nominate a clinical candidate in the first half of 2025. About MTX-463 ...

Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...

Only 2 disease-modifying idiopathic pulmonary fibrosis (IPF) therapies have been approved by the US Food and Drug Administration (FDA) as of June 2025. They do not stop or cure the disease, so the use ...